ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential

BACKGROUND: Alemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In previous phase II and III clinical trials, alemtuzumab has proven superior efficacy to subcutaneous interferon beta-1a concerning relapse rate and disability progression wi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Neurol
Päätekijät: Ruck, Tobias, Afzali, Ali Maisam, Lukat, Karl-Friedrich, Eveslage, Maria, Gross, Catharina C., Pfeuffer, Steffen, Bittner, Stefan, Klotz, Luisa, Melzer, Nico, Wiendl, Heinz, Meuth, Sven G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2016
Aiheet:
Study Protocol
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4785638/
https://ncbi.nlm.nih.gov/pubmed/26966029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-016-0556-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia